vs

Side-by-side financial comparison of Virginia National Bankshares Corp (VABK) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.

X4 Pharmaceuticals, Inc is the larger business by last-quarter revenue ($28.8M vs $15.0M, roughly 1.9× Virginia National Bankshares Corp). Virginia National Bankshares Corp runs the higher net margin — 39.7% vs 1.0%, a 38.7% gap on every dollar of revenue.

United Bankshares, Inc. is a bank holding company dual-headquartered in Charleston, West Virginia and Fairfax, Virginia with operations in West Virginia, Virginia, the District of Columbia, Maryland, Ohio, Pennsylvania, North Carolina, South Carolina, and Georgia in the United States. United Bankshares is the parent company of United Bank which comprises nearly 250 offices in eight states. In addition, UBSI is the parent company to subsidiaries George Mason Mortgage, United Brokerage, and Cre...

X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.

VABK vs XFOR — Head-to-Head

Bigger by revenue
XFOR
XFOR
1.9× larger
XFOR
$28.8M
$15.0M
VABK
Higher net margin
VABK
VABK
38.7% more per $
VABK
39.7%
1.0%
XFOR

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
VABK
VABK
XFOR
XFOR
Revenue
$15.0M
$28.8M
Net Profit
$6.0M
$282.0K
Gross Margin
83.6%
Operating Margin
50.5%
-32.8%
Net Margin
39.7%
1.0%
Revenue YoY
3.6%
Net Profit YoY
30.6%
100.5%
EPS (diluted)
$1.10
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VABK
VABK
XFOR
XFOR
Q4 25
$15.0M
Q3 25
$14.4M
Q2 25
$14.1M
Q1 25
$14.1M
$28.8M
Q4 24
$14.5M
Q3 24
$13.5M
Q2 24
$12.9M
Q1 24
$13.1M
$0
Net Profit
VABK
VABK
XFOR
XFOR
Q4 25
$6.0M
Q3 25
$4.6M
Q2 25
$4.2M
Q1 25
$4.5M
$282.0K
Q4 24
$4.6M
Q3 24
$4.6M
Q2 24
$4.2M
Q1 24
$3.6M
$-51.8M
Gross Margin
VABK
VABK
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
83.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
VABK
VABK
XFOR
XFOR
Q4 25
50.5%
Q3 25
39.4%
Q2 25
38.4%
Q1 25
38.4%
-32.8%
Q4 24
40.3%
Q3 24
41.9%
Q2 24
39.5%
Q1 24
32.9%
Net Margin
VABK
VABK
XFOR
XFOR
Q4 25
39.7%
Q3 25
31.7%
Q2 25
30.0%
Q1 25
31.9%
1.0%
Q4 24
31.4%
Q3 24
34.1%
Q2 24
32.3%
Q1 24
27.8%
EPS (diluted)
VABK
VABK
XFOR
XFOR
Q4 25
$1.10
Q3 25
$0.84
Q2 25
$0.78
Q1 25
$0.83
$0.04
Q4 24
$0.85
Q3 24
$0.85
Q2 24
$0.77
Q1 24
$0.68
$-7.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VABK
VABK
XFOR
XFOR
Cash + ST InvestmentsLiquidity on hand
$40.3M
Total DebtLower is stronger
$75.0M
Stockholders' EquityBook value
$184.2M
$22.9M
Total Assets
$1.6B
$130.0M
Debt / EquityLower = less leverage
3.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VABK
VABK
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
$40.3M
Q4 24
Q3 24
Q2 24
Q1 24
$60.5M
Total Debt
VABK
VABK
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
$75.0M
Q4 24
Q3 24
Q2 24
Q1 24
$55.0M
Stockholders' Equity
VABK
VABK
XFOR
XFOR
Q4 25
$184.2M
Q3 25
$177.4M
Q2 25
$170.8M
Q1 25
$166.8M
$22.9M
Q4 24
$160.3M
Q3 24
$165.9M
Q2 24
$154.2M
Q1 24
$152.6M
$1.0M
Total Assets
VABK
VABK
XFOR
XFOR
Q4 25
$1.6B
Q3 25
$1.6B
Q2 25
$1.6B
Q1 25
$1.6B
$130.0M
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.6B
$112.2M
Debt / Equity
VABK
VABK
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
3.27×
Q4 24
Q3 24
Q2 24
Q1 24
53.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VABK
VABK
XFOR
XFOR
Operating Cash FlowLast quarter
$21.3M
$-12.4M
Free Cash FlowOCF − Capex
$20.8M
FCF MarginFCF / Revenue
138.2%
Capex IntensityCapex / Revenue
3.9%
0.0%
Cash ConversionOCF / Net Profit
3.58×
-43.86×
TTM Free Cash FlowTrailing 4 quarters
$35.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VABK
VABK
XFOR
XFOR
Q4 25
$21.3M
Q3 25
$6.0M
Q2 25
$6.7M
Q1 25
$2.1M
$-12.4M
Q4 24
$15.3M
Q3 24
$15.2M
Q2 24
$-6.4M
Q1 24
$3.2M
$-33.6M
Free Cash Flow
VABK
VABK
XFOR
XFOR
Q4 25
$20.8M
Q3 25
$5.9M
Q2 25
$6.7M
Q1 25
$1.8M
Q4 24
$14.6M
Q3 24
$15.1M
Q2 24
$-6.8M
Q1 24
$3.1M
$-33.7M
FCF Margin
VABK
VABK
XFOR
XFOR
Q4 25
138.2%
Q3 25
41.0%
Q2 25
47.6%
Q1 25
13.0%
Q4 24
100.4%
Q3 24
111.7%
Q2 24
-53.0%
Q1 24
23.9%
Capex Intensity
VABK
VABK
XFOR
XFOR
Q4 25
3.9%
Q3 25
0.5%
Q2 25
0.2%
Q1 25
1.8%
0.0%
Q4 24
5.1%
Q3 24
0.9%
Q2 24
3.1%
Q1 24
0.2%
Cash Conversion
VABK
VABK
XFOR
XFOR
Q4 25
3.58×
Q3 25
1.31×
Q2 25
1.59×
Q1 25
0.47×
-43.86×
Q4 24
3.35×
Q3 24
3.30×
Q2 24
-1.54×
Q1 24
0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons